CRSP Stock Price Today (September 2026) — CRISPR Therapeutics AG Analysis & Key Metrics 2026-09-03
CRISPR Therapeutics AG (CRSP) is trading at $56.49, down 0.76% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $75.24 (33.2% upside).
- Volatility remains elevated (57.01% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.41% YoY) alongside significant competitive pressures.
CRSP Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
CRISPR Therapeutics AG - Historical Price & Volume
Market Cap
Enterprise Value: $4.00B
P/E Ratio
Forward P/E: -16.29
Revenue Growth
Year over Year
Analyst Target
+33.2% upside potential
Key Investor Questions About CRSP
What investors need to know before buying
Based on current market data, CRSP presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 51.13)
- Fundamentals say: Caution warranted (high leverage concerns)
CRSP's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CRSP investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $783.75M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, CRSP stock traded between $44.12 and $78.48—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 57.01% annualized volatility and β=1.46, the stock exhibits high sensitivity to market moves—making CRSP suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
We'll know a little more about the company's prospects by the end of the year.
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As CTX310 Data Impresses
CRISPR Therapeutics stock has climbed in the shorter term but still carries a heavy five year loss, and current valuation checks point to a company that does not clearly screen as either cheap or expensive. For investors looking at CRISPR Therapeutics today, the share price near US$56.82 sits against a mixed valuation read and a long term track record that remains in the red. The stock has fallen 52.9% over 5 years, which means long term holders are still under water despite more recent...
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding
Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.
Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says
Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia
Explore More Analysis for CRSP
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is currently trading at $56.49. The RSI (14-day) is at 51.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $75.24 implies 33.2% upside from current levels. Volatility is high at 57.0% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for CRISPR Therapeutics AG (CRSP): The trailing P/E ratio is -12.15, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -16.29, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 3.13. Price-to-Sales is 407.87. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 17 analysts covering CRSP, the consensus price target is $75.24. This represents a 33.2% upside from the current price of $56.49. The range spans from a low target of $44.00 to a high target of $110.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
CRISPR Therapeutics AG (CRSP) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for CRISPR Therapeutics AG (CRSP) investors include: 1. High volatility (57.0% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (23.0% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is CRISPR Therapeutics AG's (CRSP) current debt and financial health profile: Total debt stands at $783.75M. The debt-to-equity ratio is 44.87, which is moderate and generally manageable for most companies. The current ratio is 17.85, indicating strong short-term liquidity. The quick ratio is 17.79. The company holds $2.36B in cash and equivalents. Free cash flow is negative at $-215,845,872, which could limit the company's ability to manage debt obligations.